EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Unraveling the Genetic Landscape of Langerhans Cell Histiocytosis in Korean Patients: Comprehensive Insights from Mutational Profiles and Clinical Correlations

Kyung-Nam Koh, Ha Ra Jun, Ji-Young Lee, Ji Young Kim, Su Hyun Yoon, Young Kwon Koh, Sung Han Kang, Hyery Kim, Ho Joon Im, Sung-Min Chun

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.782 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Kyung-Nam Koh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine…. Hauptthemen laut MEDLINE: Histiocytosis, Langerhans-Cell, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korea Disease Control and Prevention Agency, Asan Institute for Life Sciences, Asan Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to conduct a comprehensive genetic analysis of patients with Langerhans cell histiocytosis (LCH), focusing on the frequency of mitogen-activated protein kinase (MAPK) pathway mutations, detailed mutation profiles of MAPK pathway genes, and their correlation with clinical features and prognosis in Korean LCH patients.Materials and Methods We performed targeted next-generation sequencing, capable of capturing exons from 382 cancer-related genes, on genomic DNA extracted from formaldehyde-fixed and paraffin-embedded samples of 45 pathologically confirmed LCH patients.

Results

The majority of patients (91.1%) exhibited single-system disease, with bone being the most common location (84.4%). Initial treatments varied, and no patients died during a median follow-up of 6.8 years. Our genetic assays revealed that all patients had MAPK pathway alterations, including BRAF mutations in 51.2%, MAP2K1 mutations in 42.2%, RAF1 mutations in 4.4%, and a KRAS mutation in 2.2%. These mutations were mutually exclusive. Detailed mutation profiles indicated that among the BRAF mutations, there were 18 point mutations and five in-frame deletions, while most MAP2K1 mutations were in-frame deletions, with only one missense mutation. We detected previously unreported variations of point mutations in BRAF, MAP2K1, KRAS, and the first instance of a RAF1-KLC1 fusion in LCH. MAP2K1 mutations occurred more frequently in older patients, whereas BRAF V600 mutations were commonly associated with unifocal bone disease. Genetic mutations did not correlate with high-risk features or event-free survival.

Conclusion

This study identified mutually exclusive MAPK pathway mutations in every LCH patient through comprehensive genetic analysis, highlighting the importance of inclusive testing in understanding the disease’s genetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histiocytosis, Langerhans-CellMutationHumansMaleFemaleRepublic of KoreaChildChild, PreschoolAdolescentInfantAdultYoung AdultHigh-Throughput Nucleotide SequencingPrognosisProto-Oncogene Proteins B-rafDNA Mutational AnalysisMAP Kinase Signaling SystemMAP Kinase Kinase 1

Stichwörter der Autor:innen

BRAFGenetic analysisLangerhans cell histiocytosisMAPKNext-generation sequencing

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanMAP2K1 protein, humanMAP Kinase Kinase 1

Autor:innen und Institutionen

  • Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Pediatrics, Chosun University College of Medicine, Gwangju, Korea.

Förderung

  • Korea Disease Control and Prevention Agency
  • Asan Institute for Life Sciences, Asan Medical Center

Zitieren

APA

Koh, K. N., Jun, H. R., Lee, J. Y., Kim, J. Y., Yoon, S. H., Koh, Y. K., Kang, S. H., Kim, H., Im, H. J., & Chun, S. M. (2025). Unraveling the Genetic Landscape of Langerhans Cell Histiocytosis in Korean Patients: Comprehensive Insights from Mutational Profiles and Clinical Correlations. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.782

Vancouver

Koh KN, Jun HR, Lee JY, Kim JY, Yoon SH, Koh YK, et al. Unraveling the Genetic Landscape of Langerhans Cell Histiocytosis in Korean Patients: Comprehensive Insights from Mutational Profiles and Clinical Correlations. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.782

BibTeX
@article{Koh2025,
  author = {Koh, Kyung-Nam and Jun, Ha Ra and Lee, Ji-Young and Kim, Ji Young and Yoon, Su Hyun and Koh, Young Kwon and Kang, Sung Han and Kim, Hyery and Im, Ho Joon and Chun, Sung-Min},
  title = {Unraveling the Genetic Landscape of Langerhans Cell Histiocytosis in Korean Patients: Comprehensive Insights from Mutational Profiles and Clinical Correlations},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.782}
}
Kostenlos starten →